{"classes":[{"categories":[{"measurements":[{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants died.","groupId":"OG000","lowerLimit":"45.24","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Overall survival was defined as the time in months between the first dose date (Day 1) and the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with recurrent, advanced locoregional disease or distant metastatic disease who did not receive any prior chemotherapy received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 28-day cycle (Q4W).","id":"OG000","title":"Chemotherapy: Naïve"},{"description":"Participants with disease not responding to prior chemotherapy received retifanlimab 500 mg, administered by IV infusion over 60 minutes on Day 1 Q4W.","id":"OG001","title":"Chemotherapy: Refractory"}],"paramType":"MEDIAN","populationDescription":"Safety Evaluable Population. Analysis was based on the chemotherapy-naïve subset of the population. Median overall survival time was estimated using the Kaplan-Meier method. CI for median overall survival time was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","timeFrame":"up to 60.4 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}